Journal of Biological Chemistry · 2007 · 37 citations · 17 references
Life SciencesBiochemistryMolecular BiologyEnzymologyMetabolismProtein EngineeringAmino Acid MetabolismAmino Acid Metabolism DisordersEnzyme DeficienciesEnzyme FunctionProtein Engineering Of EnzymesTherapeutic Protein EngineeringAmino Acid Metabolism In The LiverEnzyme Deficiency In Amino Acid MetabolismEnzyme Replacement TherapyEnzymesMetabolic Disorder TherapyPhenylalanine MetabolismRecombinant Fusion ProteinsTherapeutic Targeting Of Fusion Proteins
Metabolic diseases arise from mutations in key enzymes of major metabolic pathways. One promising approach for the treatment of such diseases is based on the administration of a wild-type enzyme to substitute the activity of the impaired enzyme by the use of enzyme replacement therapy, yet it is important to deliver this enzyme to the specific deficient tissue. We suggest a new concept for the treatment of metabolic diseases using fusion proteins. We examined the feasibility of this concept in the well characterized metabolic disease, phenylketonuria (PKU), which results from a mutation in the liver enzyme phenylalanine hydroxylase (PAH). PAH is a key enzyme in the metabolic pathway of phenylalanine. Deficiency in PAH leads to high and persistent levels of this amino acid in the plasma of PKU patients, causing permanent neurological damage. Currently a low protein diet is still considered the only effective treatment for most PKU patients. To restore PAH activity in the liver of PKU patients, we constructed PAH-based fusion proteins with delivery moieties based on the HIV-transactivator of transcription peptide, and fragments of human hepatocyte growth factor aiming to specifically target PAH to the liver. We show that these new fusion proteins can be delivered into a variety of human liver cell lines and retain PAH activity after being internalized. We also show that plasma phenylalanine levels were dramatically lowered in mice treated with PAH-based fusion proteins after intravenous administration. We therefore suggest an alternative concept for the treatment of PKU using targeted fusion proteins, which may also be applied to the treatment of other metabolic diseases.
17
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Steven R. Schwarze, Alan L. Ho, Adamina Vocero-Akbani et al. · Science · 1999 · 2.4K citations
Identification of a Competitive HGF Antagonist Encoded by an Alternative Transcript
Andrew M. Chan, Jeffrey S. Rubin, Donald P. Bottaro et al. · Science · 1991 · 220 citations
Christineh N. Sarkissian, Zhongqi Shao, Françoise Blain et al. · Proceedings of the National Academy of Sciences · 1999 · 211 citations · Full text